Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania

    loading  Checking for direct PDF access through Ovid

Abstract

Aims:

Evaluate the impact of quetiapine extended release (XR) versus quetiapine immediate release (IR) on hospitalization length in acute bipolar mania using Truven Health Analytics MarketScan® Hospital Drug Database.

Patients & methods:

Generalized linear model analyses were used, adjusting for patient and hospital characteristics.

Results:

Using data from 3088 discharges, quetiapine XR reduced hospitalization length by 6.7% versus quetiapine IR (p = 0.11; no statistically significant differences between groups), corresponding to 0.6 fewer days in hospital. Excluding the outlier, quetiapine XR significantly reduced hospitalization length by 9.6% versus quetiapine IR (p = 0.02), corresponding to 0.9 days.

Conclusion:

Inpatient use of quetiapine XR in acute bipolar mania may be associated with reduced hospitalization length (7–10%), possibly owing to the faster titration schedule versus quetiapine IR.

Related Topics

    loading  Loading Related Articles